Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis

SS Haas; R Ge; I Agartz; GP Amminger; OA Andreassen; P Bachman; I Baeza; S Choi; T Colibazzi; VL Cropley; C De La Fuente-Sandoval; BH Ebdrup; A Fortea; P Fusar-Poli; BY Glenthøj; LB Glenthøj; KM Haut; RA Hayes; K Heekeren; CI Hooker; WJ Hwang; N Jahanshad; M Kaess; K Kasai; N Katagiri; M Kim; J Kindler; S Koike; TD Kristensen; JS Kwon; SM Lawrie; I Lebedeva; J Lee; ILJ Lemmers-Jansen; A Lin; X Ma; DH Mathalon; P McGuire; C Michel; R Mizrahi; M Mizuno; P Møller; R Mora-Durán; B Nelson; T Nemoto; M Nordentoft; D Nordholm; MA Omelchenko; C Pantelis; JC Pariente; JM Raghava; F Reyes-Madrigal; JI Røssberg; W Rössler; DF Salisbury; D Sasabayashi; U Schall; L Smigielski; G Sugranyes; M Suzuki; T Takahashi; CK Tamnes; A Theodoridou; SI Thomopoulos; PM Thompson; AS Tomyshev; PJ Uhlhaas; TG Værnes; TAMJ Van Amelsvoort; TGM Van Erp; JA Waltz; C Wenneberg; LT Westlye; SJ Wood; JH Zhou; D Hernaus; M Jalbrzikowski; RS Kahn; CM Corcoran; S Frangou

Journal article

Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis

SS Haas, R Ge, I Agartz, GP Amminger, OA Andreassen, P Bachman, I Baeza, S Choi, T Colibazzi, VL Cropley, C De La Fuente-Sandoval, BH Ebdrup, A Fortea, P Fusar-Poli, BY Glenthøj, LB Glenthøj, KM Haut, RA Hayes, K Heekeren, CI Hooker Show all

JAMA Psychiatry | Published : 2024

DOI: 10.1001/jamapsychiatry.2023.3850

Abstract

Importance: The lack of robust neuroanatomical markers of psychosis risk has been traditionally attributed to heterogeneity. A complementary hypothesis is that variation in neuroanatomical measures in individuals at psychosis risk may be nested within the range observed in healthy individuals. Objective: To quantify deviations from the normative range of neuroanatomical variation in individuals at clinical high risk for psychosis (CHR-P) and evaluate their overlap with healthy variation and their association with positive symptoms, cognition, and conversion to a psychotic disorder. Design, Setting, and Participants: This case-control study used clinical-, IQ-, and neuroimaging software (Free..

View full abstract

University of Melbourne Researchers

Paul Amminger Author

Vanessa Cropley Author

Barnaby Nelson Author

Christos Pantelis Author

Related Projects (4)

NEUROINFLAMMATION IN SCHIZOPHRENIA

This project will investigate whether brain inflammation contributes to progressive brain volume loss in people with schizophrenia. Using no..

CAN WE PREDICT PSYCHOSIS AND CAN IT BE PREVENTED?

It remains unclear what the causes of schizophrenia and other psychotic disorders are and what the most effective interventions are for prev..

TRANSLATING MEMBRANE PROTEINS INTO THERAPEUTICS; FROM BEDSIDE TO BENCH

ENIGMA-COINSTAC: ADVANCED WORLDWIDE TRANSDIAGNOSTIC ANALYSIS OF VALENCE SYSTEM BRAIN CIRCUITS

Grants

Awarded by Korea Brain Research Institute

Funding Acknowledgements

This study was supported by grants PI15/0444, PI18/0242, PI18/00976, and PI2100330 from the Alicia Koplowitz Foundation and the Spanish Ministry of Health (Dr Sugranyes); 30112 (Dr Kristensen) and 26731 (Dr Sugranyes) from the Brain & Behavior Research Foundation; 261895 and 320662 from the Consejo Nacional de Ciencia y Tecnologia (Dr de la Fuente-Sandoval); 101057529 from the European Commission (Dr Sugranyes); 802998 from the European Research Council (DrWestlye); INT19/00021 (Dr Baeza) and PI11/1349, PI15/0444, and PI180242 (Drs Baeza and Fortea and Mr Pariente) from the Instituto de Salud Carlos III; JP18dm0307001, JP18dm0307004, and JP19dm0207069 (Drs Kasai and Koike) and JP19dk0307069s0203 (Dr Suzuki) from the Japan Agency for Medical Research and Development; JP18K15509 and JP22K15745 (Dr Sasabayashi), JP20H03598 (Dr Suzuki), and JP18K07550 (Dr Takahashi) from the KAKENHI program of the Japan Society for the Promotion of Science; JPMJMS2021 from the Moonshot Research and Development program of the Japan Science and Technology Agency (Drs Kasai and Koike); 21-BR-03-01 (Dr Kim) and 21-BR-03-01 (Dr Kwon) from the KBRI Basic Research Program of the Korea Brain Research Institute funded by ITC and the Ministry of Science; HI19C1080 from the Korea Health Technology Research and Development Project (Dr Hwang); R25-A2701 and R287-2018-1485 from the Lundbeck Foundation (Dr Nordholm); NMRC/TCR/003/2008 from the Translational and Clinical Research Flagship Programme of the National Medical Research Council (Dr Lee); 2019R1C1C1002457 (Dr Kim) and 2020M3E5D9079910 (Dr Kwon) from the National Research Foundation of Korea; 1177370 and 1065742 (Dr Cropley), 2010063 (Dr Lin), 1137687 (Dr Nelson), 1196508 and 1150083 (Dr Pantelis), and 569259 (Dr Schall) from the NHMRC of Australia; R21 MH117434 (Dr de la Fuente-Sandoval), R01 MH105246 (Dr Hayes), R01 MH113533 (Dr Salisbury), and R01MH107558 and R01MH115332 (Dr Corcoran) from the NIH; T32MH122394 (Dr Haas), 5T32MH15144 and K23 MH85063 (Dr Colibazzi), R01MH105246 (Dr Haut), R01 MH076989 (Dr Mathalon), R01MH100043 and R01MH113564 (Dr Mizrahi), R01MH123163, R01MH121246, and R01MH116147 (Ms Thomopoulos and Dr Thompson), 5R01MH115031 (DrWaltz), and K01MH112774 and R01MH129636 (Dr Jalbrzikowski) from the NIMH; 223272 (Dr Agartz), 223273 and 283798 (Dr Andreassen), and 223273, 288083, and 323951 (Dr Tamnes) from the Research Council of Norway; 22-15-00437 (Dr Kwon) and 22-15-00437 (Mr Tomyshev) from the Russian Science Foundation; 2019069, 2021070, 2023012, and 500189 from the South-Eastern Norway Regional Health Authority (Dr Tamnes); and MR/L011689/1 from the UK Medical Research Council (Dr Uhlhaas); and funding from the Brain & Behavior Research Foundation (Drs Colibazzi, Mathalon, and Mizrahi), the Canadian Institutes of Health Research (Dr Mizrahi), a Columbia University Bodini Fellowship (Dr Colibazzi), the Consejo Nacional de Ciencia y Tecnologia Sistema Nacional de Investigadores (Drs de la Fuente-Sandoval and Reyes-Madrigal), the Danish Research Council on Independent Research (Dr L. Glenthoj), a Herbert Irving Scholar Award (Dr Colibazzi), K. G. Jebsen Stiftelsen (Dr Andreassen), the Lundbeck Foundation Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research (Drs B. Glenthoj and L. Glenthoj), the Lundbeck Foundation Centre of Excellence for Clinical Intervention and Neuropsychiatric Schizophrenia Research (Dr L.r Glenthoj), Mental Health Center Copenhagen (Dr Nordentoft), the Mental Health Services Capital Region of Denmark (Drs Nordentoft and Nordholm), the NHMRC of Australia (DrWood), Otsuka Pharmaceutical (Dr Nemoto), the Sackler Institute (Dr Colibazzi), TrygFoundation (Dr L. Glenthoj), UiO: Life Science (Dr Andreassen), the University of Copenhagen (Dr Nordentoft), the University of Pittsburgh Medical Center (Dr Hayes), the Yong Loo Lin School of Medicine at the National University of Singapore (Dr Zhou), and the Zurich Program for Sustainable Development of Mental Health Services (Dr Rossler). Core funding for Enhancing Neuroimaging Genetics Through Meta-analysis (ENIGMA) was provided by grant U54 EB020403 from the NIH Big Data to Knowledge program (Dr Thompson).